ExSURE PVT. LTD. logo

ExSURE PVT. LTD.

EXSURE is an R & D-based startup and we are developing the next generation of exosome-based cancer therapeutics. We are developing a unique exosome-based chemotherapeutic drug-delivery platform that will facilitate precise and guided delivery of anti-cancer drugs (existing on the market) into tumor cells and relapse-causing cells (cancer stem cells) without abruptly harming the healthy cells. Our platform will reduce chemotoxicity and chances of cancer relapse in cancer patients. Currently, we are working with a breast cancer model. We have validated the efficiency and efficacy of our platform in vitro (in different breast cancer cell lines and derived cancer stem cells) and ex-vivo (primary cells & stem cells derived from chemo-naive clinical samples of breast tumor biopsies). We are yet to validate our platform in vivo (SCID mice). We have filed the patent for the formulation we are using to develop these bioengineered drug-loaded targeted exosomes and the methodology behind it (Final patent to be filed this month). We are providing outsourcing services including any type of cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.

https://exsure.in/
2-10 employees
ExSURE PVT. LTD. logo

ExSURE PVT. LTD.

Exsure is an R&D-focused Indian biotech startup pioneering exosome-based targeted drug delivery platforms for cancer treatment.

Company Size

2-10 employees

Location

India

About

EXSURE is an R & D-based startup and we are developing the next generation of exosome-based cancer therapeutics. We are developing a unique exosome-based chemotherapeutic drug-delivery platform that will facilitate precise and guided delivery of anti-cancer drugs (existing on the market) into tumor cells and relapse-causing cells (cancer stem cells) without abruptly harming the healthy cells. Our platform will reduce chemotoxicity and chances of cancer relapse in cancer patients. Currently, we are working with a breast cancer model. We have validated the efficiency and efficacy of our platform in vitro (in different breast cancer cell lines and derived cancer stem cells) and ex-vivo (primary cells & stem cells derived from chemo-naive clinical samples of breast tumor biopsies). We are yet to validate our platform in vivo (SCID mice). We have filed the patent for the formulation we are using to develop these bioengineered drug-loaded targeted exosomes and the methodology behind it (Final patent to be filed this month). We are providing outsourcing services including any type of cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.

Needs Assessment

Active buying signals and potential business opportunities

Technology Requirements

Exosome isolation reagents

Lymphocyte separation reagents

Reagents and kits for exosome isolation, lymphocyte separation, and lipid quantification.

Exosome engineering tools

Exosome isolation and engineering technologies.

Drug delivery systems

Diagnostic assays

Exosome isolation and characterization technologies.

PBMC isolation reagents

Reagents for exosome modification and drug loading

Service Requirements

Grant writing support and guidance

Research and development in exosome-based applications.

Science & Service

Book Exosure

Cancer-stem cell based Outsourcing services

Exosome-based Outsourcing services

Isolation of exosomes from various sources

Characterization of exosomes isolated from various sources.

Generation of bioengineered targeted exosomes and drug delivery.

Exosome isolation and characterization services

Drug loading services

Custom exosome engineering services

Infrastructure Requirements

Cell culture facilities

Bioengineering equipment

Plate reader

Cell culture facilities, bioengineering equipment.

Laboratory equipment for cell culture and exosome analysis

Cell culture facilities, exosome isolation and characterization equipment, drug loading systems.

Molecular biology laboratories.

Molecular biology labs

Talent Requirements

Expertise in exosome biology, cancer stem cell targeting, and nano drug delivery.

Scientific staff to support exosome isolation, characterization, and engineering.

Research and development scientists focused on exosome-based therapeutics.

Professionals with experience in regulatory compliance and clinical trials.

Team scaling needs

Experience in glycoengineering

AI Insights

Growth Trajectory

Exsure secured a seed fund of ₹3 Cr from Unicorn India and is actively developing new products, indicating strong growth potential in the biotechnology sector.

Market Opportunity

Exsure's first patented exosome-based platform in India provides a significant competitive advantage in the growing market for targeted cancer therapies, positioning them for market expansion and innovation.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats